NMDA receptors, mGluR5, and endocannabinoids are involved in a cascade leading to hippocampal long-term depression

Keyphrases

• N-methyl-D-aspartate Receptor (NMDAR) 100%
• Endocannabinoids 100%
• Metabotropic Glutamate Receptor 5 (mGluR5) 100%
• Long-term Depression 100%
• Low-frequency Stimulation 35%
• Cannabinoid Receptor 1 (CB1R) 30%
• Chloro 25%
• D-p-hydroxyphenylglycine 25%
• Noladin Ether 25%
• Receptor Agonist 10%
• Cannabinoid 1 Receptor Antagonist 10%
• Receptor Activation 5%
• Anandamide 5%
• 2-Arachidonoylglycerol (2-AG) 5%
• CA1 Region 5%
• Small Degree 5%
• Synthetic Cannabinoids 5%
• Group I mGluRs 5%
• Rat Hippocampus 5%
• Schaffer Collateral Pathway 5%
• MGluR 5%

Neuroscience

• NMDA Receptor 100%
• Metabotropic Glutamate Receptor 5 100%
• Long-Term Depression 100%
• Endocannabinoid 100%
• Cannabinoid 1 Receptor 40%
• Electrotherapy 35%
• Agonist 15%
• Receptor Antagonist 10%
• Receptor Agonists 10%
• Dihydroxyphenylglycine 10%
• Hippocampus 5%
• Aspartic Acid 5%
• Schaffer Collateral 5%
• Anandamide 5%
• 2-Arachidonoylglycerol 5%
• 3,5 Dihydroxyphenylglycine 5%
• 2 Chloro 5 Hydroxyphenylglycine 5%
• Receptor 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Endocannabinoid 100%
• Metabotropic Receptor 5 100%
• N Methyl Dextro Aspartic Acid Receptor 100%
• Noladin Ether 62%
• Cannabinoid 1 Receptor 50%
• Cannabinoid 1 Receptor Antagonist 25%
• Cannabinoid 1 Receptor Agonist 25%
• Receptor 12%
• Aspartic Acid 12%
• 2-Arachidonoylglycerol 12%
• Anandamide 12%
• 2 Chloro 5 Hydroxyphenylglycine 12%
• 3,5 Dihydroxyphenylglycine 12%